ReviewHuman vaccines & immunotherapeutics2020
Targeting the IL-9 pathway in cancer immunotherapy.
Review in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Nature communications · 2024Trial
- Macrophage-intrinsic and IL-9-dependent arginine metabolism promotes lung tumor growth.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Fucosyltransferase 4-derived peptide bioconjugates on carbon nanotubes enhance antitumor immunity in an ovarian cancer mouse model.Frontiers in immunology · 2026Article
- Interplay between microRNAs and TGF-β signaling in T cells: implications for Th9 differentiation and immune pathogenesis.Frontiers in immunology · 2026Review
- Preliminary results suggest the potential of evaluating combined bFGF and TNF-β concentrations for differentiating papillary thyroid cancer from benign nodular goiter.Scientific reports · 2025Article
- Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using LuminexCancer biomarkers : section A of Disease markers · 2025Article
- Ferroptosis: CD8Cell death discovery · 2025Review
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
- Platelets as a potential new immune coordinator in T cell-mediated aplastic anemia.Frontiers in oncology · 2025Review
- Article
- Functional diversity and regulation of IL-9-producing T cells in cancer immunotherapy.Cancer letters · 2024Review
- Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.Journal of medicinal chemistry · 2024Article
- Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer.Experimental hematology & oncology · 2024Article
- Review
- Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin.Molecular and clinical oncology · 2024Article
- CD4+ T-cell subsets in autoimmune hepatitis: A review.Hepatology communications · 2023Review
- Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses.Journal of translational medicine · 2023Article
- Upregulated Expression of the IL-9 Receptor on TRAF3-Deficient B Lymphocytes Confers Ig Isotype Switching Responsiveness to IL-9 in the Presence of Antigen Receptor Engagement and IL-4.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- The crosstalk of CD8+ T cells and ferroptosis in cancer.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin (IL)-9 is a pleiotropic cytokine, which can function as a positive or negative regulator of immune responses on multiple types of cells. The role of IL-9 was originally known in allergic disease and parasite infections. Interestingly, recent studies demonstrate its presence in the tumor tissues of mice and humans, and the association between IL-9 and tumor progression has been revisited following the discovery of T helper (Th) 9 cells. Tumor-specific Th9 cells are considered to be the main subset of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.